AMGND Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.20 |
| 52 Week High | US$11.70 |
| 52 Week Low | US$7.67 |
| Beta | 0.60 |
| 11 Month Change | 0% |
| 3 Month Change | -2.61% |
| 1 Year Change | 23.53% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 61.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMGND | AR Biotechs | AR Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 23.5% | 0% | 0% |
Return vs Industry: AMGND exceeded the AR Biotechs industry which returned 10.6% over the past year.
Return vs Market: AMGND underperformed the AR Market which returned 195.1% over the past year.
Price Volatility
| AMGND volatility | |
|---|---|
| AMGND Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in AR Market | 0% |
| 10% least volatile stocks in AR Market | 0% |
Stable Share Price: AMGND has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AMGND's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
| AMGND fundamental statistics | |
|---|---|
| Market cap | US$177.81b |
| Earnings (TTM) | US$3.13b |
| Revenue (TTM) | US$30.93b |
53.7x
P/E Ratio5.4x
P/S RatioIs AMGND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGND income statement (TTM) | |
|---|---|
| Revenue | US$30.93b |
| Cost of Revenue | US$11.32b |
| Gross Profit | US$19.62b |
| Other Expenses | US$16.49b |
| Earnings | US$3.13b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 5.83 |
| Gross Margin | 63.41% |
| Net Profit Margin | 10.12% |
| Debt/Equity Ratio | 1,057.3% |
How did AMGND perform over the long term?
See historical performance and comparison